← Issue №18/ week of Nov 1, 2026/Endoscopy

The changing role of the gastroenterologist in the management of advanced gastric cancer.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy review · Oct 31, 2026 · Dig Liver Dis · IF 4.2

The changing role of the gastroenterologist in the management of advanced gastric cancer.

Guideline / reviewbiomarkerendoscopy quality
Clinical takeawayEnsure adequate endoscopic sampling for reliable molecular profiling and collaborate with pathologists and oncologists to standardize biomarker assessment and therapeutic allocation, addressing challenges like tumor heterogeneity and testing variability.
What it foundBiomarker-driven strategies, including HER2, PD-L1, MSI/MMR deficiency, Claudin-18.2, and emerging targets like FGFR2b and EBV status, guide targeted therapies and immune checkpoint inhibitors in advanced gastric cancer.
ContextConfirms the critical role of gastroenterologists in obtaining representative tumor tissue for biomarker-driven treatment decisions, emphasizing the importance of multidisciplinary collaboration and addressing challenges like spatial and temporal tumor heterogeneity, limited tissue availability, and variability in testing methods.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Cannizzaro R … Pinto C · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues